Neurofibromatoses In Clinical Practice

This issue of Medical Clinics of North America, guest edited by Dr. Howard P. Levy, is devoted to Genetics and Precision Medicine. Articles in this important issue include: Family History in Genetics and Precision Medicine; Genetic Testing: Who, What, When and Why; Test Result Disclosure and When to Consult a Geneticist or Genetic Counselor; Patient Engagement to Inform a Large-scale Population Sequencing Program; Pharmacogenetics: Prescribing Precisely; DNA Testing for Early Cancer Diagnosis; Breast Cancer: BRCA and Beyond; Colon Cancer and Other GI Cancers; Neurofibromatosis and Related Disorders; Marfan, Loeys Dietz, and Other Syndromes Causing Arterial Fragility; Ehlers Danlos Syndromes and Related Disorders of Connective Tissue; Parkinson, Alzheimer, and Other Neuropsychiatric Diseases; Genetic Neurologic and Neuromuscular Disorders; and Polycystic Kidney Disease and Other Genetic Kidney Disorders. A CME program is also available for this title.

A thoughtful and clinically valuable account which will aid both treatment of and research into this difficult disorder.

Neurofibromatoses: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Additional Research in a compact format. The editors have built Neurofibromatoses: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Additional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Neurofibromatoses: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Part of the 'Oxford Textbooks in Clinical Neurology' series, this volume covers the pathophysiology, diagnosis, classification, and management of tumours of the nervous system.

A comprehensive review of the clinical and genetic aspects of a disease that affects over one million people worldwide, based on the cumulative experience of the longest continuously functioning program of its kind (Riccardi directs The Neurofibromatosis Institute, Pasadena, California--his vantage point is that of an accumulated 3,700 patient-years of direct observation and follow-up of patients with NF, and a total of 22,900 patient-years, counting from the time of birth until either death or January 1991). Thoroughly revised and updated (first edition, 1986) to include the latest advances in molecular biology and methods of treatment, and contains a glossary and extensive bibliography (well over 1,000 citations). Annotation copyrighted by Book News, Inc., Portland, OR

This authoritative textbook embodies the current standard in molecular testing for practicing pathologists, and residents and fellows in training. The text is organized into eight sections: genetics, inherited cancers, infectious disease, neoplastic hematopathology, solid tumors, HLA typing, identity testing, and laboratory management. Discussion of each diagnostic test includes its clinical significance, available assays, quality control and lab issues, interpretation, and reasons for testing. Coverage extends to HIV, hepatitis, developmental disorders, bioterrorism, warfare organisms, lymphomas, breast cancer and melanoma, forensics, parentage, and much more. Includes 189 illustrations, 45 in full-color. This textbook is a classic in the making and a must-have reference.

"The editors...have done an outstanding job of presenting...complex information in a lucid manner – this book is a must-read for the global community of aspiring students and neuro-oncology practitioners." Amar Gajjar, MD in the Foreword This is a succinct introduction to pediatric neuro-oncology. It summarizes the key advances in molecular biology that have helped transform this rapidly evolving field and provides up-to-date coverage of major and emerging treatment modalities as well as supportive care. Separate chapters present each kind of pediatric brain cancer and its diagnosis and treatment. As more children survive brain cancer, the importance of quality of life issues and helping survivors to cope with the neuropsychological impact and long-term effects of current therapies has come into sharper focus; these topics are also addressed in the book, as are palliative care and pediatric neuro-oncology in countries with limited resources. The book is aimed at trainees and practitioners who seek an up-to-date text in pediatric neuro-oncology that is both comprehensive and concise.

The neurofibromatoses are autosomal-dominant genetic disorders of the nervous system that primarily affect the development and growth of neural cell tissue. These disorders cause tumors to grow on nerves and produce other abnormalities such as skin changes and bone deformities. In recent years, the genes and mutations causing neurofibromatoses have been identified. The main types of neurofibromatoses, type 1 (NF1) and type 2 (NF2), have been shown to be distinctive disorders both clinically and genetically. More recently, allelic and non-allelic subtypes of NF1 have been defined as well as the NF2-related condition schwannomatosis. Many of the complex molecular mechanisms leading to the neurofibromatoses have been elucidated, resulting in a growing body of publications which are difficult to keep up with.This volume provides an important overview of recent findings on the neurofibromatoses. It focuses on the genetics and molecular biology underlying these diseases, but also covers their clinical features, diagnosis and treatment, stressing the need for interdisciplinary medical care. With contributions by the foremost investigators in the field, this timely book will appeal to geneticists, genetic counselors, pediatricians, neurologists and oncologists.

Neurofibromatoses in Clinical PracticeSpringer Science & Business Media

The development of new technology in hearing aid devices as well as imaging techniques has improved the possibilities of meeting the patient's individual needs. This book, in which experts from around the world have contributed, comprehensively covers advances in all aspects of hearing implantation otology. Chapters review the evidence behind the current applications of the

wide range of hearing implants available for different types of hearing loss. Further articles discuss the extended applications of implantation otology and let us have a glimpse into the future of hearing rehabilitation. New imaging techniques for the middle and inner ear are explored as well as innovations to improve Eustachian tube function. The publication is essential reading to otolaryngologists, audiologists and hearing rehabilitation professionals. It provides comprehensive coverage of state of the art hearing rehabilitation across the spectrum of hearing loss: as such it is a perfect tool for those who wish to develop their knowledge within the field.

Here is the state-of-the-art on recognizing, managing and living with neurofibromatosis (NF) for patients, families, and health care professionals. From new genetic and diagnostic advances, to associated cardiovascular and endocrine abnormalities, to the significant psychosocial impact of NF, the book is packed with clear, practical guidance for understanding and living with this disability.Special features: A complete diagnostic guide to help you recognize NF-related symptoms--with a timeline for when they might appear New treatment options for NF, including pain control Coverage of the newly discovered form of NF, schwannomatosis Personal perspectives from NF patients and their families Glossary that defines medical terminology With the great diagnostic and treatment advances achieved in the last decade, and research proceeding rapidly, the future for patients with NF has never been brighter. For all individuals living with the challenges of this disability, the book brings you to the forefront of medical knowledge. Make sure it is within close reach for fast and easy reference.

Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Build your Foundation of Basic Science – from Research to Clinical Application A great tool for MOC preparation! A 'must have' for residency! This fourth edition, developed in a partnership between the American Academy of Orthopaedic Surgeons (AAOS) and the Orthopaedic Research Society (ORS), is your concise and clinically relevant resource for the diagnosis and treatment of musculoskeletal diseases and conditions.

Neurofibromatosis type 1 (NF1) is a common autosomal dominantly inherited, tumour predisposition syndrome affecting 1/3,000-4,000 individuals worldwide. This inherited disorder results from the mutational inactivation of the NF1 gene on human chromosome 17. The NF1 gene contains 61 exons that give rise to 12kb mRNA encoding neurofibromin. The 327kDa (2,818 amino acid) neurofibromin protein is expressed in most tissues and has a number of alternative isoforms. Neurofibromin is a tumour suppressor protein and down-regulates cellular Ras. Increased active Ras- GTP levels also stimulate the important PI3K/AKT/mTOR signalling pathway that protects cells from apoptosis. The major clinical features of NF1 include multiple café-au-lait rmacules, skinfold freckles, iris Lisch nodules, and neurofibromas. The diagnostic criteria for clinical diagnosis have been well established. However, there are a small number of cases in which the diagnosis is not certain. The germline mutation rate for the NF1 gene is 10-fold higher than that observed for most other inherited diseases. Using a combination of different techniques, almost 95% of germline mutations can be detected. To date, only two firm genotype phenotype correlations have been reported. NF1 phenotype exhibits large variations within a family, evidence for modifying loci regulating the expression of an NF1 gene is beginning to emerge. We also are gaining knowledge on the molecular mechanisms associated with the development of different types of tumours. It is encouraging that the results of recent laboratory and clinical research are finally being translated into clinical trials. With the availability of high-throughput technologies, sophisticated animal models, and multi-centre clinical trials, the future for NF1 sufferers is looking optimistic. This book aims to provide an overview of the genetic and clinical aspects of NF1 and its role in both NF1-associated and sporadic tumour development. It emphasizes the recent developments in this field and some of the promising on-going clinical trials.

This title reflects the exponential growth in the knowledge and information on this subject and defines the extensive clinical translation of cardiovascular genetics and genomics in clinical practice. This concise, clinically oriented text is targeted at a broad range of clinicians who manage patients and families with a wide range of heterogeneous inherited cardiovascular conditions. Cardiovascular Genetics and Genomics: Principles and Clinical Practice includes a concise and clear account on selected topics written by a team of leading experts on clinical cardiovascular genetics. Each chapter include key information to assist the clinician and case histories have been incorporated to reflect contemporary practice in clinical cardiovascular genetics and genomics. Therefore this will be of key importance to all professionals working in the discipline, from clinicians and trainees in cardiology, cardiac surgery, electrophysiology, immunology through geneticists, nursing staff and those involved in precision medicine.

This highly anticipated new edition brings together an expert group of authors to provide a comprehensive, systematic resource on genetic diseases of the eye. This richly illustrated title covers areas such as: malformations; refractive errors, the cornea, glaucoma and cataracts; retina and the optic nerve; eye movement disorders, and systemic disease of the eye. The new edition remains grounded in a sound clinical approach to the patient with a genetic disease that affects the eye. Oxford Genetics is a comprehensive, cross-searchable collection of resources offering quick and easy access to Oxford University Press's prestigious genetics texts. Joining Oxford Medicine Online these resources offer students, specialists and clinical researchers the best quality content in an easy-to-access format. Online only benefits include downloading images and figures to PowerPoint and downloading chapters to PDF.

This comprehensive, yet practical, text is a ready collection of the most up-to-date information on primary CNS tumors. Authored by a carefully selected group of the world’s leading clinicians and scientists, the book is divided into three sections. The opening chapters cover general principles, including epidemiology, pathogenesis, tumor stem cells, supportive care, complications of therapy, and quality of life. The remaining two sections are comprised of treatment-oriented chapters covering the spectrum of gliomas and rarer tumor types. Each of these chapters presents multi-disciplinary therapeutic approaches and addresses specific disease concerns. Throughout, the authors incorporate the cutting-edge advances in molecular biology and genomics that are revolutionizing neuro-oncology. The result is an important clinical resource which provides evidence-based data and interpretation essential to intelligent therapeutic decision making.

Neurofibromatosis: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Additional Research in a concise format. The editors have built Neurofibromatosis: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Additional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Neurofibromatosis: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts,

research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

The editors of this comprehensive third edition of the Textbook of the Neurogenic Bladder have assembled an impressive team of world specialists to develop an essential resource for physicians, continence specialists, and other health care professionals involved in the diagnosis and management of patients who have lost normal bladder function.The b

The most recent update to one of the most essential references on medical genetics Cassidy and Allanson's Management of Genetic Syndromes, 4th Edition is the latest version of a classic text in medical genetics. With newly covered disorders and cutting-edge, up-to-date information, this resource remains the most crucial reference on the management of genetic syndromes for students, clinicians, and researchers in the field of medical genetics. The 4th edition includes current information on the identification of genetic syndromes (including newly developed diagnostic criteria), the genetic basis (including diagnostic testing), and the routine care and management for more than 60 genetic disorders. Each, "expert authored", chapter includes sections on: Incidence Diagnostic criteria Etiology, pathogenesis and genetics Diagnostic testing Differential diagnosis Manifestations and Management (by system) The book focuses on genetic syndromes, primarily those involving developmental disabilities and congenital defects. The chapter sections dealing with Manifestations and Management represents the centerpiece of each entry and is unmatched by other genetic syndrome references. Management of Genetic Syndromes is perfect for medical geneticists, genetic counselors, primary care physicians and all health care professionals seeking to stay current on the routine care and management of individuals with genetic disorders.

FIRST PRIZE Winner in the Oncology category of the 2010 BMA Medical Book Competition. Intensive research over the last fifteen years has yielded a vast expansion in our understanding of the role of inheritance and genetics in a variety of cancers. Several inherited conditions have been identified which result in a high risk of various cancers; some of these were previously recognized, but the genetic basis underlying them has now been elucidated. This knowledge is now entering the sphere of routine clinical care. Surgeons, gastroenterologists, gynaecologists, oncologists, endocrinologists and many others need an awareness of these disorders, an understanding of genetic testing and when it is indicated, and how to manage patients with inherited cancer predisposition and their families. This book covers the basic concepts of cancer genetics. The common inherited cancer syndromes are each dealt with in greater depth, with the current management outlined. This book is aimed at all clinicians who may encounter these conditions in their practice. It aims to facilitate identification of high-risk individuals and families, to inform interaction with geneticists and other subspecialists, to provide a basis for patient management and to stimulate interest in these fascinating conditions.

Neurofibromatosis, one of the most common genetic disorders, is a group of three conditions—Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis—that share some clinical features, such as the presence of cranial and spinal nerve sheet tumors. However, they differ in type of genetic disorder, age of clinical onset, manifestations, management and prognosis. Due to multisystem involvement, a multidisciplinary treatment approach that includes research is ideal. This book provides a systematic, comprehensive and updated outline of Neurofibromatosis. It is a useful reference for clinicians, researchers and students.

Neurofibromatosis type 1 (NF1), caused by mutational inactivation of the NF1 tumour suppressor gene, is one of the most common dominantly inherited human disorders, affecting 1 in 3000 individuals worldwide. This book presents in concise fashion, but as comprehensively as possible, our current state of knowledge on the molecular genetics, molecular biology and cellular biology of this tumour predisposition syndrome. Written by internationally recognized experts in the field, the 44 chapters that constitute this edited volume provide the reader with a broad overview of the clinical features of the disease, the structure and expression of the NF1 gene, its germ line and somatic mutational spectra and genotype-phenotype relationships, the structure and function of its protein product (neurofibromin), NF1 modifying loci, the molecular pathology of NF1-associated tumours, animal models of the disease, psycho-social aspects and future prospects for therapeutic treatment.

Neurofibromatosis: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Neurofibromatosis in a concise format. The editors have built Neurofibromatosis: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Neurofibromatosis in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Neurofibromatosis: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

This issue of Dermatologic Clinics, guest edited by Dr. Lindsay C. Strowd of Wake Forest Baptist Health, is devoted to the Intersection of Dermatology and Oncology. This issue focuses on Melanoma, Nonmelanoma Skin Cancer, Cutaneous Lymphoma, Other Cutaneous Malignancies, Special Topics in Skin Cancer Diagnosis and Treatment, Dermatology in the Diagnosis of Non-cutaneous Malignancy, Dermatology in the Management of Non-cutaneous Malignancy, and Genodermatoses with Neoplastic Behavior. Articles in this issue include: Update on current treatment recommendations for primary cutaneous melanoma; Nonsurgical treatments for advanced melanoma; Update on current treatment recommendations for NMSC; Nonsurgical treatments for NMSC; Diagnosis and management of CBCL; Diagnosis and management of CTCL; Lymphomatoid papulosis and other lymphoma-like diseases (PLC, PLEVA, CD30+ disease); Dermatofibrosarcoma protuberans updates; Merkel cell carcinoma updates; Kaposi sarcoma updates; Skin cancer in skin of color patients; Skin cancer detection technology; Paraneoplastic diseases; Cutaneous metastases of internal tumors; Cutaneous side effects of chemotherapy agents; GVHD treatment updates; Phakomatoses (NF, TS); and Hereditary tumor syndromes with skin involvement (Gorlins, Lynch, XP, etc.).

This volume offers an update of the clinical signs, diagnostic criteria (including molecular diagnosis) and targeted therapies for a particular type of genodermatosis, providing a handy and unique tool for early diagnosis. In recent years, our understanding of genodermatosis and neurocutaneous syndromes has increased, but although Type 1 Neurofibromatosis (NF1) is the most common neuroectodermal disorder and involves a large number of patients and medical disciplines, this syndrome remains underestimated, often misdiagnosed thus leading to inaccurate treatment. The literature on the molecular and pathogenetic aspects is ample, but current clinical approaches, classification, diagnostic criteria and treatment protocols are outdated, creating difficulties in early diagnosis and treatment. As such, a chapter is devoted renewing current diagnostic criteria; it includes clinical and molecular data, to offer a sound, updated discussion basis for a consensus conference. NF1 is a “time-dependent” disorder, meaning that the onset of clinical signs are closely linked to patient age and the book discusses this particularly neglected aspect extensively, as well as the latest molecular diagnosis techniques, which are highly sensitive have not been included in the diagnostic criteria. It also explains the role of the RAS-MAPK pathway and genotype-phenotype correlations. In addition it explores new concepts concerning the pathogenesis of neurofibromas and other hamarthomas and their relevance for a modern therapeutical approach with targeted molecular drugs, as well as newly discovered aspects of NF1 in all internal organs, together with their diagnostic counterparts. A chapter on mosaic neurofibromatosis is also included. There is a particular focus on differential diagnosis (i.e. other diseases with café-au-lait macules), and the recently described Legius syndrome will be presented directly by Prof Eric Legius. All chapters are easy-to-understand, up-to-date, comprehensive and concise tools and are intended for a wide range of professionals involved with genetic disorders of the skin and neurocutaneous diseases: dermatologists, pediatricians, neurologists, oncologists and general practitioners.

This book summarises the entire field of adult neuro-urology in a concise, well-illustrated, and practical style. Contents include epidemiology, lower urinary tract anatomy and physiology. This is followed by coverage of the pathophysiology of various types of voiding dysfunctions and a clinical section focusing on practical evaluation and treatment. A range of treatments from behavioral, pharmacological, intra vesical, tissue engineering and surgical are explained and reviewed. Other topics such as complications, sexual function, fertility, maternity aspects, and prognostic factors round off the book. *Each topic is covered in detail and well illustrated. *The reader will gain a full understanding of every aspect of adult neuro-urology. *Facilitates improved clinical knowledge and practice. Provides an essential and complete reference tool for students and established urologists, neurologists, physiotherapists and nurses, and technicians involved in the care of patients with neurogenic bladder dysfunction.

Neurofibromatosis: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Neurofibromatosis in a compact format. The editors have built Neurofibromatosis: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Neurofibromatosis in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Neurofibromatosis: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Neurofibromatosis Type 1: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Neurofibromatosis Type 1 in a compact format. The editors have built Neurofibromatosis Type 1: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Neurofibromatosis Type 1 in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Neurofibromatosis Type 1: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

In the growing field of neuro-oncology, the past few years have witnessed rapid advances in tumor classification, treatment modalities, and the role of neurologists and neuro-oncologists. Neuro-Oncology for the Clinical Neurologist is a first-of-its-kind resource that focuses on patient-clinical scenarios relevant to the practicing neurologist—bringing you up to date with everything from basic principles and neuro-oncology imaging consults to neurologic complications of radiation, systemic, and immune-based therapies, and much more. Focuses on the clinical management of patients typically encountered by neurologists and neurology trainees. Provides clinically relevant updates in five key areas of neuro-oncology: primary CNS tumors, brain and leptomeningeal metastases, inherited tumor syndromes of the nervous system (e.g. neurofibromatosis), paraneoplastic and immune-mediated neurological complications of cancer, and neurological complications of cancer treatments. Includes a summary of clinical pearls and a reference list of clinical cases. Anchors each chapter with patient cases and clinical scenarios, provides evidence-based discussion, and explains patient management. Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

In this book, internationally recognized experts review the most important advances regarding the group of human developmental disorders caused by constitutive dysregulation of the Ras-MAPK signalling pathway, including Noonan, cardiofaciocutaneous, LEOPARD and Costello syndromes. A historical overview given by Jacqueline Noonan is followed by chapters dedicated to comprehensive clinical summaries of each condition and up-to-date reviews on associated gene mutations and molecular pathomechanisms. Genotypephenotype correlations are outlined.

Further topics include the characterization and underlying mechanisms of common abnormalities in these syndromes such as growth failure, heart defects, and tumor risk. Animal models and the relation to neurofibromatosis type 1 are discussed. The final chapter covers the critical area of treatment including prospects emerging from an improved understanding of the pathophysiology of these disorders. Providing a concise overview of a very rapidly developing field and suggesting ways how to integrate the latest findings from basic molecular research into clinical practice, this book will be of interest to clinical geneticists, pediatricians, pediatric cardiologists, and pediatric endocrinologists, as well as to human molecular geneticists and other basic researchers working on the RAS pathway.

A modernizing revision will make it one of the most comprehensive books that incorporate new findings in growing areas of neurology, memory, genetics, imaging and biochemistry - while retaining the book's traditional size, scope, focus, and successful uniform organization. New research findings, combined with several new and updated tables and figures, the book provides reliable guidelines on diagnosis and treatment of all neurological conditions and disorders.

Acoustic neuroma outcomes have been greatly improved by advances in microsurgical techniques, and recently by the long-term application of radiosurgery, which has proven to be an appropriate, verifiable, and extremely clinically relevant treatment strategy. This volume brings together the latest opinions of outstanding physicians and surgeons who treat patients with acoustic neuromas, commonly known as vestibular neuromas. Since the days of Cushing, when partial tumor removal seemed the best method for saving a patient's life, the management of this relatively rare tumor has sparked enormous clinical interest. The book outlines the various stages in the evolution of vestibular schwannoma surgery and presents the full spectrum of current therapeutic possibilities. The novel concept of combining microsurgical with radiosurgical skills should eliminate problems such as facial palsy and hearing loss which were previously associated with the therapeutic management of these tumors. The excellent research findings published here by leading experts in the field will help neurosurgeons, otologists and radiation oncologists to understand the enormous strides made during the last two decades in vestibular schwannoma surgery and radiosurgery.

Diagnosis and management of adult and pediatric genetic disorders Experts in otorhinolaryngology as well as medical genetics have contributed their reviews to this comprehensive compilation. Introductory chapters deal with basic genetics followed by chapters devoted to specific disorders. The gamut of otorhinolaryngological diseases from both adult and pediatric practice is covered. Included are common disorders such as hearing loss, cleft lip and palate, and thyroid cancers as well as further chapters on rare disorders such as Usher syndrome, neurofibromatosis type 2 and paraganglioma. Also, emerging fields of genetic investigation including otitis media, chronic rhinosinusitis and gene therapy are discussed. The contributions focus on diagnosis and management, as well as practical issues like how to order genetic testing or refer to a medical geneticist or genetic counselor. This publication will serve as an educational and reference text for both adult and pediatric otorhinolaryngologists, as well as medical geneticists and genetic counselors. It will provide readers with an understanding of the current state of genetic disorders seen in ORL practice, allow for accurate diagnosis, and improve patient management.

Neurofibromatoses in Clinical Practice provides a succinct, accessible guide to the neurofibromatoses including diagnosis, management protocols and indications for referral to specialist centers. Neurocutaneous diseases are complex to diagnose and treat and many patients require specialist multidisciplinary management and surveillance. Due to multiple disease manifestations, patients can present to different clinicians without specialist expertise - general practitioners, pediatricians, neurologists, geneticists, surgeons and ophthalmologists. The clinically focused format will enable rapid consultation during clinics, facilitate disease pattern recognition, and indicate care pathways. The clinical quiz highlights common pitfalls in diagnosis and management and a glossary and reference section provide details for access to specialist NF clinics throughout the UK and internationally. Written by experts in the field Neurofibromatoses in Clinical Practice is a succinct and practical guide for consultants in training and practice, general practitioners and specialist nurses.